PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

ABSTRACT:

SUBMITTER: Vitolo U 

PROVIDER: S-EPMC9428988 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature